Synergy Pharmaceuticals to Begin Trading on The NASDAQ Global Market
11 Fevereiro 2013 - 8:00AM
Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new
drugs to treat gastrointestinal disorders and diseases, today
announced that its common stock has been approved for listing on
The NASDAQ Global Market under the symbol "SGYP." Trading on The
NASDAQ Global Market is expected to commence on February 12, 2013.
The Company's units and warrants will continue to trade on The
NASDAQ Capital Market under the symbols "SGYPU" and "SGYPW,"
respectively.
About Synergy Pharmaceuticals Inc.
Synergy is a biopharmaceutical company focused on the
development of new drugs to treat gastrointestinal disorders and
diseases. Synergy's lead proprietary drug candidate, plecanatide,
is a synthetic analog of the human gastrointestinal hormone
uroguanylin, and functions by activating the guanylate cyclase C
receptor on epithelial cells of the GI tract. Synergy completed a
positive Phase I study of plecanatide in healthy volunteers, and
positive Phase IIa and Phase IIb/III clinical trials in patients
with chronic idiopathic constipation (CIC). Detailed positive
findings from a recently completed Phase IIb/III clinical trial
will be presented at a major scientific meeting this year. Synergy
is also developing plecanatide for the treatment of irritable bowel
syndrome with constipation (IBS-C), having initiated the first
trial in IBS-C patients in late 2012. Synergy's second GC-C
agonist, SP-333, is in clinical development to treat inflammatory
bowel diseases, and has just completed its first Phase I trial in
healthy volunteers. More information is available at
http://www.synergypharma.com.
CONTACT: Media Contact:
Janet Skidmore
Office: 215-658-4915
Mobile: 215-429-2917
skidmorecomm@earthlink.net
Investor Contact:
Danielle Spangler
The Trout Group
synergy@troutgroup.com
(646) 378-2924
Synergy Pharmaceuticals - Warrants (NASDAQ:SGYPW)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Synergy Pharmaceuticals - Warrants (NASDAQ:SGYPW)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre Synergy Pharmaceuticals - Warrants da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de